

**ABSTRACT**

The invention regards the use of triiodothyronine sulfate, commonly named **T<sub>3</sub>S**, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (**T<sub>3</sub>**), as such or in association with thyroxine (**T<sub>4</sub>**), and pharmaceutical formulations thereof.